FDAmanufacturing / CMC95% confidence
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable manufacturing / CMC decision relevant to Incyte; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · JAK Inhibitor
- Sub-indication
- General
Related signal: FDA Approves JAKAFI XR for Incyte Corp.